David Hoang
Stock Analyst at Deutsche Bank
(4.06)
# 522
Out of 5,134 analysts
47
Total ratings
57.89%
Success rate
12.68%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Hoang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APGE Apogee Therapeutics | Initiates: Buy | $103 | $69.64 | +47.90% | 1 | Dec 10, 2025 | |
| ALKS Alkermes | Maintains: Buy | $55 → $45 | $32.90 | +36.78% | 3 | Nov 13, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Buy | $65 → $280 | $328.04 | -14.64% | 2 | Oct 17, 2025 | |
| SYRE Spyre Therapeutics | Initiates: Buy | $43 | $35.95 | +19.61% | 1 | Sep 26, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Buy | $54 → $36 | $36.92 | -2.49% | 4 | Sep 25, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Sell | $6 → $12 | $17.88 | -32.89% | 10 | Aug 15, 2025 | |
| ACAD ACADIA Pharmaceuticals | Upgrades: Buy | $20 → $35 | $22.95 | +52.51% | 5 | May 21, 2025 | |
| XENE Xenon Pharmaceuticals | Initiates: Buy | $67 | $41.66 | +60.83% | 3 | Feb 11, 2025 | |
| DNLI Denali Therapeutics | Initiates: Buy | $31 | $19.28 | +60.79% | 3 | Feb 11, 2025 | |
| BHVN Biohaven | Initiates: Buy | $65 | $11.48 | +466.20% | 1 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $176 | $183.30 | -3.98% | 4 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $150 → $158 | $127.76 | +23.67% | 4 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $2.45 | +185.71% | 1 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $5.50 | +190.91% | 1 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $3.41 | +369.21% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $220 | $332.61 | -33.86% | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $80 | $63.69 | +25.61% | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $3 | $2.15 | +39.53% | 1 | Dec 7, 2022 |
Apogee Therapeutics
Dec 10, 2025
Initiates: Buy
Price Target: $103
Current: $69.64
Upside: +47.90%
Alkermes
Nov 13, 2025
Maintains: Buy
Price Target: $55 → $45
Current: $32.90
Upside: +36.78%
Praxis Precision Medicines
Oct 17, 2025
Maintains: Buy
Price Target: $65 → $280
Current: $328.04
Upside: -14.64%
Spyre Therapeutics
Sep 26, 2025
Initiates: Buy
Price Target: $43
Current: $35.95
Upside: +19.61%
Harmony Biosciences Holdings
Sep 25, 2025
Maintains: Buy
Price Target: $54 → $36
Current: $36.92
Upside: -2.49%
Sarepta Therapeutics
Aug 15, 2025
Maintains: Sell
Price Target: $6 → $12
Current: $17.88
Upside: -32.89%
ACADIA Pharmaceuticals
May 21, 2025
Upgrades: Buy
Price Target: $20 → $35
Current: $22.95
Upside: +52.51%
Xenon Pharmaceuticals
Feb 11, 2025
Initiates: Buy
Price Target: $67
Current: $41.66
Upside: +60.83%
Denali Therapeutics
Feb 11, 2025
Initiates: Buy
Price Target: $31
Current: $19.28
Upside: +60.79%
Biohaven
Feb 11, 2025
Initiates: Buy
Price Target: $65
Current: $11.48
Upside: +466.20%
Feb 11, 2025
Initiates: Buy
Price Target: $176
Current: $183.30
Upside: -3.98%
Aug 2, 2024
Maintains: Neutral
Price Target: $150 → $158
Current: $127.76
Upside: +23.67%
Jul 25, 2024
Initiates: Buy
Price Target: $7
Current: $2.45
Upside: +185.71%
Mar 15, 2024
Initiates: Buy
Price Target: $16
Current: $5.50
Upside: +190.91%
Mar 7, 2024
Initiates: Buy
Price Target: $16
Current: $3.41
Upside: +369.21%
Apr 26, 2023
Initiates: Neutral
Price Target: $220
Current: $332.61
Upside: -33.86%
Apr 26, 2023
Initiates: Outperform
Price Target: $80
Current: $63.69
Upside: +25.61%
Dec 7, 2022
Downgrades: Neutral
Price Target: $3
Current: $2.15
Upside: +39.53%